We previously reported that a Kozak sequence variant in the metabotropic glutamate receptor 3 gene (*GRM3*), rs148754219, is associated with bipolar disorder (BP) and affects gene transcription and translation ([@R1]). A marker near *GRM3*, rs12704290, is one of the top hits and reached genome-wide significance in a recently reported genome-wide association study of schizophrenia (SZ) ([@R5]), and markers for *GRM3* have also been reported to demonstrate association with alcohol dependence syndrome (ADS) ([@R3]). In our original sample, considering patients successfully genotyped for rs148754219, 19 out of 1062 BP cases and only four out of 932 controls were heterozygous \[odds ratio (OR)=4.2 (1.4--12.3), *P*=0.005\]. We have genotyped this variant in additional controls and cases diagnosed with BP, SZ and ADS with the same ancestry. Patients were assessed by trained clinicians as described previously ([@R1]; [@R6]). Allele counts were compared and significance was tested using Fisher's exact test. Thirteen out of 934 additional BP cases and three out of 377 additional controls were heterozygous \[OR=1.8 (0.49--6.2), *P*=not significant\]. Combined with the originally reported results ([@R1]), 32 out of 1964 BP cases and seven out of 1309 controls were heterozygous \[OR=3.0 (1.3--6.8), *P*=0.003\]. Out of 1235 SZ cases 16 were heterozygous and were compared with the total control sample \[OR=2.4 (0.99--5.8), *P*=0.03\]. Out of 1514 ADS cases 18 were heterozygous and one was homozygous for the variant allele \[OR=2.5 (1.0--5.9), *P*=0.03\]. If all case cohorts (BP, SZ and ADS) are combined together, there would be one homozygote and 66 heterozygotes out of 4971 cases compared with the seven heterozygotes out of 1309 controls \[OR=2.7 (1.2--5.8), *P*=0.004\]. Previous work has supported the view that some genetic risk factors may be common to different psychiatric diagnoses ([@R4]; [@R2]). Although the individual results are of questionable significance, the magnitude and direction of effect are consistent across all the cohorts and thus suggest the possibility that this rare variant may have a direct, functional effect on the risk of developing any of these three disorders. Because of its rarity, large sample sizes would be needed to confirm these results. Doing this would be worthwhile because if this finding is confirmed it could provide molecular insight into a mechanism involving *GRM3* leading to increased risk of mental disorders and could provide a basis for further functional and therapeutic studies.
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